Key statistics
On Monday, Allarity Therapeutics Inc (ALLR:NAQ) closed at 0.995, 62.10% above the 52 week low of 0.6138 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.97 |
|---|---|
| High | 0.9999 |
| Low | 0.97 |
| Bid | 0.97 |
| Offer | 0.9999 |
| Previous close | 0.97 |
| Average volume | 142.74k |
|---|---|
| Shares outstanding | 16.08m |
| Free float | 15.53m |
| P/E (TTM) | -- |
| Market cap | 15.60m USD |
| EPS (TTM) | -2.31 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
- Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
- Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
- Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
- Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
- Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
- Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
- Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
- Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
- Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
More ▼
